敏實集團(00425.HK)7月28日授出2800萬份購股權
格隆匯7月28日丨敏實集團(00425.HK)公佈,於2020年7月28日,公司已依照公司於2012年5月22日通過的購股權計劃向一批對集團有貢獻或將作出貢獻的合資格參與者("承授人")授出購股權作為獎勵或激勵,用以認購總計2800萬股於公告發布日期每股面值為0.10港元的公司股份。每股行使價為23.85港元,有效期自2021年7月1日至2025年12月31日。其中135萬股購股權被授予下述董事及其各自連絡人,而總計2665萬股購股權被授予集團之其他部分僱員。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.